THURSDAY, Nov. 5 (HealthDay News) -- A genome sequencing company says it has developed a lower-cost DNA platforming sequence.
Its report, including an analysis of data from three full human genomes, was published Nov. 5 in Science.
The company, Complete Genomics, said the consumables cost for three genomic DNA nanoarrays ranged from $1,726 to just over $8,000.
"We've demonstrated that it's possible to accurately and affordably sequence and detect variants across entire human genomes," Cliff Reid, chairman, president and chief executive of the company, said in a news release from the company. "This high-quality, cost-effective approach to genome sequencing will allow researchers to study complete genomes from hundreds of patients with a disease to advance the understanding of the genetic causes of that disease, with an end to preventing and treating common human ailments."
The company released its findings in a study that describes how they sequenced cell lines from two people -- a white man of European descent and a Yoruban female. Researchers also sequenced lymphoblast DNA from another white man.
The company, which said its techniques save on expenses and have a low error rate, expects to be able to sequence 10,000 human genomes next year.
More information
The U.S. Department of Energy, Office of Science, has more about the human genome project.
SOURCE: Complete Genomics, news release, Nov. 5, 2009
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Today's Top News Stories |
• | Go Healthy, Not Hungry for Holiday Eating - Nov 22, 2009, 09:00
Planning ahead can help keep eating under control, expert says. |
• | When Sleep Suffers, So Does Decisiveness - Nov 21, 2009, 09:00
Not being well-rested can be dangerous for those whose jobs require quick reactions, researchers say. |
• | Stunts Raise Injury Risks for Cheerleaders - Nov 21, 2009, 09:00
Type of flooring, greater heights increase potential for trauma, study finds. |
• | Swine Flu Declining in Some Parts of U.S. - Nov 20, 2009, 16:00
But, flu activity remains high and is expected to continue, CDC says. |
• | Clinical Trials Update: Nov. 20, 2009 - Nov 20, 2009, 10:05
- H1N1 Flu Vaccine
- Atrial Fibrillation
- Rheumatoid Arthritis (RA)
|
